medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2011, Number 3

Next >>

VacciMonitor 2011; 20 (3)

A single dose of live-attenuated 638 Vibrio cholerae oral vaccine is safe and immunogenic in adult volunteers in Mozambique

García HM, Thompson R, Valera R, Fando R, Fumane J, Jani I, Mirabal M, Armesto MI, Songane M, Luis S, Nzualo AM, Celeste J, Viegas S, Samo GE, Melembe A, Bila D, Cemá C, Mabumo C, García L, Cedré B, Año G, Martínez JC, Mandarioti A, Lugones J, González D, Baró M, Hernández J, Talavera A, Solis RL, Sierra G, Barberá R, Domínguez F, Gutiérrez C, Campa C, Garrido I, Menéndez J

Language: English
References: 27
Page: 1-8
PDF size: 154.16 Kb.


ABSTRACT

A placebo-controlled randomized, double-blind, clinical trial was carried out to assess the safety, reactogenicity, and immunogenicity of the lyophilized vaccine candidate against cholera derived from the live attenuated 638 Vibrio cholerae O1 El Tor Ogawa strain. One hundred and twenty presumably healthy female and male adult volunteers aged between 18 and 50 years were included. They were from Maputo, Mozambique a cholera endemic area, where, in addition, human immunodeficiency virus (HIV) seroprevalence is from 20 to 30%. A dose of 2 x 109 colony forming units (CFU) was given to 80 subjects and other 40 received only vaccine lyoprotectors as a placebo control. Out-patient follow-up of adverse events was carried out during the following 30 days after vaccination. The immune response was evaluated by the estimation of seroconversion rate and the geometric mean titer (GMT) of vibriocidal antibodies in the sera from volunteers that was collected previously, and at days 14 and 21 after immunization. No serious adverse events were reported. The adverse events found in the vaccine group were similar to those of the placebo groups. They were independent from the detection of antibodies against HIV-1, HIV-2, hepatitis (H) A; HC and hepatitis B surface antigen. The presence of helminthes did not modify the incidence of adverse events. The 638 vaccine strain was isolated in 37 (46.25%) vaccinated volunteer’s feces. The peak of the GMT of vibriocidal antibodies in the vaccine group was 9056 versus 39 in the placebo group at 14 days with a total serocon


REFERENCES

  1. WHO. Cholera 2006. Weekly Epidemiological Record 2007:82(31):273-84.

  2. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, october 2009. Conclusions and recommendations. Weekly Epidemiological Record 2009:84(50):526-8.

  3. Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Review of Vaccines 2006;5(4):483-94.

  4. Mahalanabis D, Ramamurthy T, Nair GB, Ghosh A, Shaikh S, Sen B, et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 2009; 27:4850–6.

  5. Talavera A, Año G, García H, Moreira T, Delgado R, Riverón L, et al. Process development for Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638. Vaccine 2006;24:3746–9.

  6. Valera R, García HM, Díaz Jidy M, Mirabal M, Armesto MI, Fando R. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.Vaccine 2009;27:6564–9.

  7. Benítez JA, Silva A, Rodríguez BL, Fando R, Campos J, Robert A, et al. Genetic manipulation of V. cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains. Arch Med Res 1996;27:275–83.

  8. Robert A, Silva A, Benítez JA, Rodríguez BL, Fando R, Campos J, et al. Taggin a V. cholerae El Tor candidate vaccine strain by disruption of its hemagglutinin/protease gene using a novel reporter enzyme, Clostridium thermocellone endogluconase A. Vaccine 1996;14:1517–22.

  9. Benítez JA, García LG, Silva A, García H, Fando R, Cedré B, et al. Preliminary assessment of the safety and immunogenicity of a new CTX-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infection Immunity 1999;67:539–45.

  10. Cedré B, García H, García L, Talavera A. Estandarización y evaluación del ensayo vibriocida. Revista Cubana Medicina Tropical 1999;51:156–9.

  11. Cedré B, Viel Y, Rodríguez T, Año G, Pino Y, García H, et al. Validación del ensayo vibriocida colorimétrico para determinar anticuerpos séricos contra cepas candidatas vacunales de V. cholerae. VacciMonitor 2003;12(1):23–30.

  12. Peña MA, Valera R, Mirabal M, Rodríguez M, Armesto M, Menéndez J, et al Propuesta de un algoritmo para evaluar la causalidad de eventos adversos en los Ensayos Clínicos de Vacunas. VacciMonitor 2008;17(3):21-6.

  13. Harris JB, Podolsky MJ, Bhuiyan TR, Chowdhury F, Khan AI, LaRocque RC, et al. Immunologic responses to V. cholerae in patients co-infected with intestinal parasites in Bangladesh. PLoS Negl Trop Dis 2009;3(3):e403. Available in: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2657204/

  14. Harrell FE. Hmisc S function library; 2003. Available from: http:/ /hesweb1.med. virginia.edu/biostat/s/Hmisc.html

  15. R Development Core Team R. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2004. Available from: http://www.Rproject. org

  16. Agresti A, Coull B. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 1998;52:119–26.

  17. García L, Díaz Jidy M, García H, Rodríguez BL, Fernández R, Año G, et al. The vaccine candidate V. cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005;73:3018–24.

  18. Perry RT, Plowe CV, Koumaré B, Bougoudogo F, Kotloff KL, Losonsky GA, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bulletin of the World Health Organization 1998;76(1):63-71.

  19. Ortigão-de-Sampaio MB, Shattock RJ, Hayes P, Griffin G, Linhares-de-Carvalho MI, Ponce de Leon A, et al. Increase in plasma viral load after oral cholera immunization of HIVinfected subjects. AIDS 1998;12(14):F145-F150.

  20. Seidlein L, Wang XY, Macuamule A, Mondlane C, Puri M, Hendriksen I, et al. Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique. Tropical Medicine and International Health. 2008;13(5):683-8.

  21. Su-Arehawaratana P, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuravanont K, et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992;65:1042-8.

  22. Qadry F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 2005;192(4):573-9.

  23. Holmgren J, Svennerholm AM. Mechanisms of disease and immunity in cholera: a review. J Infect Dis 1977;136(Suppl.1):S105-12.

  24. Sahn D, LaRocque RC, Khan AI, Harris JB, Begum YA, Akramuzzaman, et al. Incomplete correlation of serum vibriocidal antibody titer with protection from V. cholerae infection in urban Bangladesh. J Infect Dis 2004;189:2318-22.

  25. WHO. Cholera 2009. Wkly Epidemiol Rec 2010:85(31):293- 308.

  26. WHO. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010.85:117–128. Available from: http://www.who.int/wer

  27. PAHO. PAHO Expertos hacen un llamado a crear una reserva internacional de la vacuna anticolérica. Disponible en: http:// new.paho.org




2020     |     www.medigraphic.com